Lorus, Cancer Research U.K. deal
Cancer Research U.K.'s Drug Development Office ( DDO) and commercial subsidiary Cancer Research Technology (CRT) Ltd. agreed to a clinical development partnership with Lorus to develop the biotech's proinflammatory cytokine interleukin-17E (IL-17E) cancer compound. Under the deal, Lorus will retain rights to the program, while the DDO will fund and conduct preclinical trials and a Phase I trial. Lorus will manufacture and supply IL-17E for the studies. After the Phase I trial, Lorus will have the exclusive option to license the Phase I trial data and resume further development. If it does not exercise the option, the rights will be transferred to CRT, which will find an alternative partner. Lorus said the deal offers an avenue to develop the IL-17E program and the opportunity to progress as many of its programs as possible into the clinic. IL-17E is the eighth treatment to enter a clinical development partnership with Cancer Research U.K. ...